The interview is outstanding...focused...compelling...but we...

The interview is outstanding...focused...compelling...but we that have had this stock for a while know this.We know the biotech fund managers have already been informed, but this was aimed at the general public...reaches 260 million households...but of course not all are tuning in at once...even so as Steven said it only requires one investor with deep pockets to see the value...and 90 million shares tightly held...each one of the trials could rerate the company many times.To back it up if any American investor looks at the web site and sees the current Edison report after seeing the TV interview it reinforces the the decision making process...lets see what happens

The interview segment can be previewed online http://www.redchip.com/media/1405/prescienttherapeutics-novel-treatments-for-a-range-of-cancers.